NorthWest Biotherapeutics Inc (NWBO)

[Barunuuk]

I cant find any recent reference, but I recall the original OS endpoint was 2 months increase as that has been the standard comparison for GBM. Termizolomide was approved on 2 month increase from SOC. ICT-107 missed the 2 month increase in its phase 2 trial. 2 months OS increase has become the standard for acceptance as an effective GBM treatment

They did update the SAP, and I dont know what the trial design was changed to, (or if it was changed) but I wouldnt doubt that the secondary endpoint OS, was moved to compare itself to SOC data with the FDA's new approval of comparing SOC data.